Direkt zum Inhalt springen
A case study: Nanoformulation for enhanced drug delivery and better patient compliance

News -

A case study: Nanoformulation for enhanced drug delivery and better patient compliance

One of the biggest challenges in bringing a new chemical entity (NCE) to market, or in realising its potential is solubility. Frequent-dose therapies in drug development mean that low drug solubility becomes a potential bottleneck for pharmaceutical formulators. This not only results in more time to bring new drugs to market, but also affects the lives of patients in need.

In this case study, Losan Pharma and BENEO pool their combined resources. In this way, we have succeeded in developing a prototype for a solid oral dosage form of dexamethasone, an active ingredient that is virtually insoluble in water and only needs to be taken once a day. The case study of a nanoformulation shows how quickly and easily even complicated once-daily products can be developed with the right technological approach.

The study has been published in IPI – International Pharmaceutical Industry:

Nanoformulation-for-Enhanced-Drug-Delivery-and-Better-Patient-Compliance.pdf (international-pharma.com)

Links

Themen

Kategorien

Kontakt

Zugehörige Meldungen

  • Novel Formulation Screening Tool

    Novel Formulation Screening Tool

    Predictive #Formulation #Screening Method - Losan Pharma, in cooperation with the University of Copenhagen, has established a standardized screening tool combining non-sink dissolution with permeation